Tenosynovial Giant Cell Tumors Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies

DelveInsight's,“ Tenosynovial Giant Cell Tumors Pipeline Insight 2025 ” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the Tenosynovial Giant Cell Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Tenosynovial Giant Cell Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Tenosynovial Giant Cell Tumors Research. Learn more about our innovative pipeline today! @ Tenosynovial Giant Cell Tumors Pipeline Outlook

Key Takeaways from the Tenosynovial Giant Cell Tumors Pipeline Report

• In July 2025, SynOx Therapeutics Limited announced a study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires.
• DelveInsight's Tenosynovial Giant Cell Tumors pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Tenosynovial Giant Cell Tumors treatment.
• The leading Tenosynovial Giant Cell Tumors Companies such as AmMax Bio Inc., Deciphera Pharmaceuticals, SynOx Therapeutics, Abbisko Therapeutics Co, Ltd., Hutchison Medipharma Limited, Elixiron Immunotherapeutics and others.
• Promising Tenosynovial Giant Cell Tumors Pipeline Therapies such as Pexidartinib, Vimseltinib, Pimicotinib(ABSK021), FPA008, Nilotinib, AMB-05X, Emactuzumab, MCS110 and others.

Download for updates and be a part of the revolution in oncology care @ Tenosynovial Giant Cell Tumors Clinical Trials Assessment

Tenosynovial Giant Cell Tumors Emerging Drugs Profile

• Vimseltinib: Deciphera Pharmaceuticals

Vimseltinib is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the CSF1R switch pocket. Vimseltinib has demonstrated encouraging preliminary efficacy and safety data in patients with TGCT. It is currently being evaluated in Phase III clinical trial to treat patients with Tenosynovial Giant Cell Tumors. The MOTION Phase III study is two-part, randomized, double-blind, placebo-controlled study of vimseltinib to assess the efficacy and safety in patients with symptomatic TGCT who are not amenable to surgery.

• EI-1071: Elixiron Immunotherapeutics

EI-1071 is a small-molecule drug that inhibits the tyrosine kinase activity of the Colony Stimulating Factor‐1 Receptor (CSF‐1R). EI‐1071 has a potentially best-in-class therapeutic index or potency-versus-toxicity profile, shows efficient blood-brain-barrier penetration and causes robust reduction of brain microglia in pre-clinical models. EI-1071 also reduces tumor-associated macrophage numbers and improves tumor control in cancer models. EI-1071 is being developed for the treatment of recurrent and/or diffuse Tenosynovial Giant Cell Tumors (TGCT), a debilitating disease of the joints driven by over-expression of CSF-1, for which a phase II trial is being planned to start in 2023.

The Tenosynovial Giant Cell Tumors Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Tenosynovial Giant Cell Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tenosynovial Giant Cell Tumors Treatment.
• Tenosynovial Giant Cell Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Tenosynovial Giant Cell Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tenosynovial Giant Cell Tumors market.

Learn more about Tenosynovial Giant Cell Tumors Drugs opportunities in our groundbreaking research and development projects @ Tenosynovial Giant Cell Tumors Unmet Needs

Tenosynovial Giant Cell Tumors Companies

AmMax Bio Inc., Deciphera Pharmaceuticals, SynOx Therapeutics, Abbisko Therapeutics Co, Ltd., Hutchison Medipharma Limited, Elixiron Immunotherapeutics and others.

Tenosynovial Giant Cell Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Tenosynovial Giant Cell Tumors Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Stay informed about how we're transforming the future of oncology @ Tenosynovial Giant Cell Tumors Market Drivers and Barriers, and Future Perspectives

Scope of the Tenosynovial Giant Cell Tumors Pipeline Report

• Coverage- Global
• Tenosynovial Giant Cell Tumors Companies- AmMax Bio Inc., Deciphera Pharmaceuticals, SynOx Therapeutics, Abbisko Therapeutics Co, Ltd., Hutchison Medipharma Limited, Elixiron Immunotherapeutics and others.
• Promising Tenosynovial Giant Cell Tumors Pipeline Therapies- Pexidartinib, Vimseltinib, Pimicotinib(ABSK021), FPA008, Nilotinib, AMB-05X, Emactuzumab, MCS110 and others.
• Tenosynovial Giant Cell Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Tenosynovial Giant Cell Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Tenosynovial Giant Cell Tumors Pipeline on our website @ Tenosynovial Giant Cell Tumors Emerging Drugs and Companies

Table of Contents